WFM
IDIX

Wilmington Funds Management’s IDENIX PHARMACEUTICALS INC IDIX Stock Holding History

Wilmington Funds Management’s Portfolio IDIX Stock Details IDIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q2 		$553K Buy
22,956
+7,500
+49% +$78.2K 0.06% 334
2014
Q1 		$93K Buy
15,456
+1,963
+15% +$13.7K 0.01% 736
2013
Q4 		$81K Sell
13,493
-16,119
-54% -$74.6K 0.01% 763
2013
Q3 		$154K Hold
29,612
– – 0.01% 716
2013
Q2 		$107K Buy
+29,612
New +$121K 0.01% 696

Other funds holding IDIX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BCPEM
Bain Capital Public Equity Management Boston, Massachusetts $1.05B AUM 25.71% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SCM
Sarissa Capital Management Greenwich, Connecticut $158M AUM 103.7% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wilmington Funds Management's IDIX Position: Q2 2014 in Review

Wilmington Funds Management increased its IDENIX PHARMACEUTICALS INC (IDIX) stake by 49% in Q2 2014, buying an estimated $78.2K and bringing the position to 22,956 shares worth $553K. The position accounts for 0.06% of the portfolio, ranked #334.

Wilmington Funds Management first reported a position in IDIX in Q2 2013 and has held it in 5 quarters since. 131 funds tracked by Wall St. Rank hold IDIX as of Q2 2014.

  • Wilmington Funds Management held 22,956 shares of IDENIX PHARMACEUTICALS INC worth $553K as of Q2 2014.
  • Wilmington Funds Management bought 7,500 IDENIX PHARMACEUTICALS INC shares in Q2 2014, an estimated $78.2K.
  • IDENIX PHARMACEUTICALS INC made up 0.06% of Wilmington Funds Management's portfolio in Q2 2014, its #334 holding.
  • Wilmington Funds Management first reported a position in IDENIX PHARMACEUTICALS INC in Q2 2013 and has held it in 5 quarters since.
  • 131 funds tracked by Wall St. Rank held IDENIX PHARMACEUTICALS INC as of Q2 2014.

Based on Wilmington Funds Management's 13F filing for Q2 2014, filed 13 Aug 2014.